TPST Key Statistics, Chart & Performance
The current stock price of TPST is 2.82 USD. In the past month the price decreased by -9.62%. In the past year, price decreased by -77.15%.
TPST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 24
Phone: 14157988589
TEMPEST THERAPEUTICS INC / TPST FAQ
What does TPST do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
What is the stock price of TEMPEST THERAPEUTICS INC today?
The current stock price of TPST is 2.82 USD.
What is the dividend status of TEMPEST THERAPEUTICS INC?
TPST does not pay a dividend.
What is the ChartMill technical and fundamental rating of TPST stock?
TPST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of TPST stock?
TEMPEST THERAPEUTICS INC (TPST) has a market capitalization of 13.90M USD. This makes TPST a Nano Cap stock.
What is the next earnings date for TPST stock?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2026-03-25, after the market close.
TPST Technical Analysis
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. TPST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -10.05. The EPS increased by 50.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210.49% | ||
| ROE | -568.14% | ||
| Debt/Equity | 0 |
TPST Forecast & Estimates
6 analysts have analysed TPST and the average price target is 9.18 USD. This implies a price increase of 225.53% is expected in the next year compared to the current price of 2.82.